Angelini Pharma, a privately held Italian specialty pharma company, has struck a deal to acquire Catalyst Pharmaceuticals (CALY) for $4.1 billion — a transaction that would take the rare-disease focused biotech private. The deal represents a significant premium for a company that, per SEC filings through FY2025, reported revenues of approximately $2.1 billion on 42.1% gross margins, though net margins remain deeply negative at -19.9% with diluted EPS of -$2.20.

The $4.1 billion enterprise valuation implies roughly 2x trailing revenues — not an outlandish multiple for a specialty pharma company with a rare-disease franchise, but the negative net margins and negative EPS underscore that profitability is still a work in progress. Catalyst's flagship asset, cenobamate (Xcopri), for focal-onset seizures, has been gaining commercial traction, which likely underpins Angelini's strategic rationale for the deal.

For market participants, this is now a classic merger-arb situation. If the deal is trading at a spread to $4.1bn implied per-share value, that spread compensates holders for deal-close risk — regulatory review (antitrust is unlikely to be a major issue given the buyer is a private European strategic) and shareholder vote. The key variables are the per-share deal price versus where CALY opens on the news, and the expected time to close.

Bull case for the arb: strategic buyer, no obvious antitrust friction, premium deal with a motivated acquirer needing rare-disease scale. Bear case: deal could face financing risk (Angelini is private and must fund $4.1bn), prolonged regulatory timeline, or a competing bid that disrupts the clean arb. Traders should watch for the confirmed per-share price and any financing disclosure from Angelini.